{"id":692,"date":"2015-09-21T17:02:00","date_gmt":"2015-09-21T11:32:00","guid":{"rendered":"https:\/\/delveinsightblog.wordpress.com\/?p=692"},"modified":"2024-09-17T16:04:10","modified_gmt":"2024-09-17T10:34:10","slug":"fatty-acid-amide-hydrolase-faah-inhibitors-pipeline-insights-2015-a-delveinsights-report","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/fatty-acid-amide-hydrolase-faah-inhibitors-pipeline-insights-2015-a-delveinsights-report","title":{"rendered":"Fatty Acid Amide Hydrolase (FAAH) Inhibitors – Pipeline Insights, 2015 – A DelveInsight\u2019s Report"},"content":{"rendered":"

Fatty acid amide hydrolase (FAAH)<\/strong> is an intracellular amidase signature<\/strong> family of serine hydrolases<\/strong> enzyme, which catalyzes the hydrolysis of bioactive fatty acid ethanolamides<\/strong> such as anandamide<\/strong> and oleoylethanolamide<\/strong>. FAAH serves as the major metabolic regulator of many of the endogenous fatty acid amides<\/strong>, exhibiting a distribution consistent with its role in terminating their effects at the released sites of action. It is the only well characterized mammalian enzyme bearing their unusual Ser\u2013Ser\u2013Lys<\/strong> catalytic triad.<\/p>\n

A remarkable series of potent, selective, and efficacious inhibitors of the enzyme FAAH <\/strong>have now been disclosed, many of which have been utilized to mechanistically and structurally characterize the enzyme. In this regard, it is interesting to note that around 70 million<\/strong> Americans annually suffer from chronic disorders in sleep<\/strong>, making sleep second only to pain in the number of patients seeking medical attention.<\/p>\n

Several studies summarized in recent reviews have detailed the discovery of FAAH<\/strong> and defined its potential<\/strong> to serve as a new therapeutic target<\/strong> for the treatment of a range of clinical disorders<\/strong>. The development of inhibitors of FAAH, the enzyme responsible for degradation of endogenous oleamide<\/strong> and anandamide<\/strong> and may prove to be useful therapeutic agents for the treatment of sleep disorders and pain.<\/p>\n

Since FAAH is recognized as a drug target, a large number of inhibitors have been synthesized and tested since 1994, and these are reviewed in terms of reversibility<\/strong>, potency<\/strong>, and specificity <\/strong>for FAAH and cannabinoid receptors. An innovative clinical opportunity likely will emerge, from better understanding the fundamental physiological role of the signaling fatty acid amides, which FAAH regulates. This area is still incompletely defined.<\/p>\n

Inhibitors of FAAH are considered a potential therapeutic approach,<\/strong> for the treatment of several nervous system<\/strong> disorders, including pain<\/strong>, anxiety<\/strong>, and insomnia<\/strong>. However, for FAAH <\/strong>inhibitors to achieve clinical utility, they must not only display efficacy in vivo but also selectivity for this enzyme relative to the numerous other serine hydrolases present in mammalian proteomes.<\/p>\n

\"Featured<\/p>\n

Figure 1: Mechanism of Fatty Acid Amide Hydrolase<\/strong><\/p>\n

\u201cThe FAAH Inhibitors – Pipeline Insights, 2015\u201d report, provides information of 25+ pipeline drugs with 13+ companies <\/strong>actively involved in drug development. There are 3 drugs in phase II, 2 in phase I, 4 in pre-clinical, 1 in discovery, 14 in inactive and 1 in discontinued. <\/strong>Vernalis plc<\/strong> is developing a lead product V-158866<\/strong> which is in Phase II<\/strong>.<\/p>\n

DelveInsight <\/strong>has made strong presence in Orphan market, with 200+ <\/strong>Reports on Orphan based Indications<\/strong>, 100+ <\/strong>Reports on Oncology based Indications & Mechanism of Action (MOA), 70+ <\/strong>Reports on CVS Indications<\/strong>, 60+ <\/strong>Reports on CNS Indications<\/strong> and 15+ <\/strong>Reports on Specialized Gene Therapy.<\/strong><\/p>\n

DelveInsight\u2019s report provides Assessment over chemical<\/strong>, technology information<\/strong> and comparative analysis<\/strong> at various stages. In addition, FAAH Inhibitors – Pipeline Insights, 2015<\/strong> report will help to identify the key players of market and the potential market movers and barriers<\/strong>.<\/p>\n

DelveInsight\u2019s <\/strong>FAAH Inhibitors – Pipeline Insights, 2015<\/strong> report will help companies to optimize their portfolio by analyzing the market<\/strong> and creating effective counter-strategies<\/strong> for collaborations and licensing deals<\/strong>. Apart from this the report on FAAH Inhibitors – Pipeline Insights<\/strong> will provide the technologies<\/strong> in use that will allow the Pharma manufacturers to attain high production<\/strong> at competitive pricing. DelveInsight\u2019s also provide custom research services <\/strong>in coherence with interest area of the clients<\/strong>.<\/p>\n

DelveInsight is offering the Report at a price of USD 1,250<\/strong> as a single user license, USD 2,500<\/strong> as a site license and USD 4,000<\/strong> as a Global\/Enterprise License.<\/p>\n

For more information on our FAAH Inhibitors – Pipeline Insights reports email us at info@delveInsight.com<\/a><\/p>\n

About DelveInsight: <\/strong><\/p>\n

DelveInsight is a leading Business Consulting and Market Research Firm.  We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this, DelveInsight also deals in providing custom research services in coherence with interest area of the clients.<\/p>\n","protected":false},"excerpt":{"rendered":"

Fatty acid amide hydrolase (FAAH) is an intracellular amidase signature family of serine hydrolases enzyme, which catalyzes the hydrolysis of bioactive fatty acid ethanolamides such as anandamide and oleoylethanolamide. FAAH serves as the major metabolic regulator of many of the endogenous fatty acid amides, exhibiting a distribution consistent with its role in terminating their effects […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[245],"industry":[17225],"therapeutic_areas":[17229],"class_list":["post-692","post","type-post","status-publish","format-standard","hentry","category-articles","tag-fatty-acid-amide-hydrolase","industry-pharmaceutical","therapeutic_areas-central-nervous-system"],"acf":[],"yoast_head":"\nExploring FAAH Inhibitors: Pipeline Overview and Future Directions<\/title>\n<meta name=\"description\" content=\"Fatty acid amide hydrolase (FAAH) is an intracellular amidase signature family of serine hydrolases enzyme, which catalyzes the hydrolysis\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/fatty-acid-amide-hydrolase-faah-inhibitors-pipeline-insights-2015-a-delveinsights-report\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Exploring FAAH Inhibitors: Pipeline Overview and Future Directions\" \/>\n<meta property=\"og:description\" content=\"Fatty acid amide hydrolase (FAAH) is an intracellular amidase signature family of serine hydrolases enzyme, which catalyzes the hydrolysis\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/fatty-acid-amide-hydrolase-faah-inhibitors-pipeline-insights-2015-a-delveinsights-report\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-09-21T11:32:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-17T10:34:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/delveinsightblog.files.wordpress.com\/2015\/09\/faah1.jpg?w=263\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Exploring FAAH Inhibitors: Pipeline Overview and Future Directions","description":"Fatty acid amide hydrolase (FAAH) is an intracellular amidase signature family of serine hydrolases enzyme, which catalyzes the hydrolysis","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/fatty-acid-amide-hydrolase-faah-inhibitors-pipeline-insights-2015-a-delveinsights-report","og_locale":"en_US","og_type":"article","og_title":"Exploring FAAH Inhibitors: Pipeline Overview and Future Directions","og_description":"Fatty acid amide hydrolase (FAAH) is an intracellular amidase signature family of serine hydrolases enzyme, which catalyzes the hydrolysis","og_url":"https:\/\/www.delveinsight.com\/blog\/fatty-acid-amide-hydrolase-faah-inhibitors-pipeline-insights-2015-a-delveinsights-report","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2015-09-21T11:32:00+00:00","article_modified_time":"2024-09-17T10:34:10+00:00","og_image":[{"url":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/09\/faah1.jpg?w=263","type":"","width":"","height":""}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/fatty-acid-amide-hydrolase-faah-inhibitors-pipeline-insights-2015-a-delveinsights-report","url":"https:\/\/www.delveinsight.com\/blog\/fatty-acid-amide-hydrolase-faah-inhibitors-pipeline-insights-2015-a-delveinsights-report","name":"Exploring FAAH Inhibitors: Pipeline Overview and Future Directions","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/fatty-acid-amide-hydrolase-faah-inhibitors-pipeline-insights-2015-a-delveinsights-report#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/fatty-acid-amide-hydrolase-faah-inhibitors-pipeline-insights-2015-a-delveinsights-report#primaryimage"},"thumbnailUrl":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/09\/faah1.jpg?w=263","datePublished":"2015-09-21T11:32:00+00:00","dateModified":"2024-09-17T10:34:10+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Fatty acid amide hydrolase (FAAH) is an intracellular amidase signature family of serine hydrolases enzyme, which catalyzes the hydrolysis","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/fatty-acid-amide-hydrolase-faah-inhibitors-pipeline-insights-2015-a-delveinsights-report"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/fatty-acid-amide-hydrolase-faah-inhibitors-pipeline-insights-2015-a-delveinsights-report#primaryimage","url":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/09\/faah1.jpg?w=263","contentUrl":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/09\/faah1.jpg?w=263"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":null,"coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Fatty acid amide hydrolase<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Fatty acid amide hydrolase<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 11 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Sep 21, 2015","modified":"Updated on Sep 17, 2024"},"absolute_dates_time":{"created":"Posted on Sep 21, 2015 5:02 pm","modified":"Updated on Sep 17, 2024 4:04 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/692","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=692"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/692\/revisions"}],"predecessor-version":[{"id":29549,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/692\/revisions\/29549"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=692"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=692"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=692"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=692"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=692"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}